ClinicalTrials.gg
Not yet recruitingNCT07478328Updated Mar 17, 2026

Chaigui Longmu Ejiao Paste for Ischemic Heart Disease

A Phase 2 interventional study of Standard Western medicine treatment + Chaigui Longmu Ejiao Paste and Placebo Comparator: Standard Western medicine treatment + Chaigui Longmu Paste without Ejiao in Ischemic Heart Disease, sponsored by Longhua Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Longhua Hospital · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Myocardial Ischemia with a site in China — 20 open to participants now, 22 under way, none of them phase 3. Myocardial Ischemia · China.

Planned enrollment
36th of 48
60 · median 303
Started
2026
with 3 others
Phase 2
2 of 81
1 open now
Primary completion
2027-03
later than 11 of 21 live
Registered
77th of 81
by date

Among the 81 studies in Myocardial Ischemia with a site in China, this one is the 36th largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 2, reaches primary completion later than 11 of the 21 other live ones, and was the 77th registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

20 of the 81 studies in Myocardial Ischemia with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Myocardial Ischemia with a site in China, or all of them as a file.
02

Study summary

This study explores whether Chaigui Longmu Ejiao Paste can reduce the average weekly number of angina attacks in patients with ischemic heart disease after 8 weeks of treatment, using Chaigui Longmu Paste without Ejiao as a parallel control and incorporating a synthesized external control.

Read the detailed description

Overall Study Design: This is a randomized, double-blind clinical trial with internal and external controls.

Trial Procedure: The study includes a screening/baseline period, an 8-week treatment period, and a 4-week follow-up period. The end-of-study/end-of-treatment visit (EOS/EOT) is performed at 12 weeks after treatment initiation.

Randomization and Blinding: Block randomization is applied, with a 1:1 allocation ratio across groups. The trial is double-blinded.

External Control: Literature data (external control derived from published literature).

Data Collection: Data are collected using an Electronic Data Capture (EDC) system in combination with an electronic Patient-Reported Outcomes (ePRO) system.

03

Conditions studied

  • Ischemic Heart Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years, both sexes eligible;
  2. Meets the diagnostic criteria for stable angina pectoris in ischemic heart disease (IHD), with stable condition for ≥4 weeks;
  3. Has received standard Western medical treatment (including but not limited to antiplatelet agents, lipid-modifying/stabilizing plaque therapy, β-blockers, etc.) for at least 4 weeks, with stable dosages;
  4. Meets the Traditional Chinese Medicine (TCM) syndrome diagnostic criteria of "thoracic yang deficiency with heart vessel stasis" (or "chest yang insufficiency with heart meridian blood stasis"), with primary symptoms: chest oppression/pain, palpitations; at least 2 secondary symptoms: insomnia, aversion to cold, spontaneous sweating, irritability or restlessness; supported by tongue and pulse findings;
  5. Has signed the form and is willing to participate voluntarily in the study.

Exclusion criteria

Exclusion Criteria:

  1. Acute coronary syndrome or patients requiring emergency revascularization;
  2. Use of traditional Chinese medicine (TCM) or Chinese patent medicines with therapeutic effects on ischemic heart disease within the past 2 weeks;
  3. Poorly controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg after treatment);
  4. Severe heart failure ( functional class IV), uncontrolled malignant arrhythmias, cardiogenic shock; severe cerebrovascular diseases; active or recurrent digestive system ulcers or other diseases with bleeding risk; other severe digestive system diseases; complicated with malignant tumors, hematological disorders, or other severe or progressive systemic diseases; complicated with other mental disorders that render the patient unable or unwilling to cooperate;
  5. Severe hepatic or renal impairment (/AST > 3 × , or creatinine > 1.5 × upper limit of normal);
  6. Known allergy to any component of the study formula;
  7. Women who are pregnant, lactating, or planning pregnancy;
  8. Patients who have participated in other clinical trials within the past 3 months;
  9. Patients deemed by the investigator to be unsuitable for participation in the clinical trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Standard Western medicine treatment + Chaigui Longmu Ejiao Paste

    All patients receive standard Western medical treatment prescribed by the attending physician in accordance with the latest clinical guidelines, including but not limited to antiplatelet agents, statins, β-blockers, ACE inhibitors/ARBs, and others. Participants in the experimental arm received Chaigui Longmu Ejiao Paste 15 g orally twice daily (morning and evening) for 8 weeks.

    Drug: Standard Western medicine treatment + Chaigui Longmu Ejiao Paste

  • Placebo comparator
    Standard Western medicine treatment + Chaigui Longmu Paste without Ejiao

    All patients receive standard Western medical treatment prescribed by the attending physician in accordance with the latest clinical guidelines, including but not limited to antiplatelet agents, statins, β-blockers, ACE inhibitors/ARBs, and others. Participants received Chaigui Longmu Paste without Ejiao 15 g orally twice daily (morning and evening) for 8 weeks.

    Drug: Placebo Comparator: Standard Western medicine treatment + Chaigui Longmu Paste without Ejiao

Interventions

  • DrugStandard Western medicine treatment + Chaigui Longmu Ejiao Paste

    15 g orally twice daily

  • DrugPlacebo Comparator: Standard Western medicine treatment + Chaigui Longmu Paste without Ejiao

    15 g orally twice daily

06

What researchers measure

Primary outcomes

  1. Average weekly reduction in angina attack frequency

    The mean change in the average number of angina attacks per week from baseline to the end of the 8-week treatment period in patients with ischemic heart disease ; Recorded using electronic patient-reported outcomes (ePRO).

    Time frame: Baseline to week 8

Secondary outcomes

  1. Change from Baseline in Seattle Angina Questionnaire (SAQ) Scores

    The Seattle Angina Questionnaire (SAQ) is a validated, disease-specific, self-reported instrument that assesses health status in patients with angina due to ischemic heart disease. It measures five domains: Physical Limitation (extent of limitation in physical activity due to angina), Angina Stability (change in angina frequency over the past 4 weeks), Angina Frequency (frequency and burden of angina episodes), Treatment Satisfaction (satisfaction with angina treatment), and Disease Perception/Quality of Life (impact of angina on quality of life). Each domain is scored from 0 to 100, with higher scores indicating better health status (less limitation, fewer symptoms, greater satisfaction, better quality of life). Change = (Week 4 or Week 8 Score - Baseline Score) for each domain and the total score (overall summary score, if applicable, averaging the relevant domains).

    Time frame: Baseline, Week 4, and Week 8

  2. Average Weekly Nitroglycerin Consumption

    The average number of nitroglycerin tablets (or sublingual sprays) used per week by the participant to relieve angina symptoms. This is a key indicator of angina burden and rescue medication requirement.

    Time frame: Week 4, and Week 8

  3. Change from Baseline in Traditional Chinese Medicine (TCM) Syndrome Score

    The TCM Syndrome Score is a composite system based on the diagnostic criteria for the pattern "Chest Yang Deficiency with Heart Vessel Stasis". It assesses severity of: * Primary symptoms (chest oppression/chest pain, palpitations) * Secondary symptoms (insomnia, aversion to cold, spontaneous sweating, irritability/restlessness of heart and mind) Tongue and pulse are observed but not scored numerically. Scoring: * Primary symptoms: 0 (absent), 2 (mild), 4 (moderate), 6 (severe) * Secondary symptoms: 0 (absent), 1 (mild), 2 (moderate), 3 (severe) Total score = sum of all symptom scores. Higher score = greater severity. Change value * score at week 4 or 8 - baseline score A lower (more negative) change value indicates greater improvement in the TCM syndrome.

    Time frame: Baseline, Week 4, and Week 8

  4. Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score

    The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered, 14-item instrument that assesses the severity of anxiety symptoms. Each item is scored from 0 (none) to 4 (severe), with a total score ranging from 0 to 56 (higher scores indicate greater anxiety severity). The scale are administered by trained clinicians. Change = (Week 4 or Week 8 total score - Baseline total score) for each scale. Negative changes indicate improvement (reduction) in anxiety symptoms.

    Time frame: Baseline, Week 4, and Week 8

  5. Change from Baseline in Hamilton Depression Rating Scale (HAM-D) Score

    The Hamilton Depression Rating Scale (HAMD-24) is a clinician-administered 24-item scale used to assess the severity of depressive symptoms. Most items are scored on a 5-point scale (0 = absent to 4 = very severe), with some items scored on a 3-point scale (0 = absent to 2 = severe). Total score ranges from 0 to approximately 76, with higher scores indicating greater severity of depression. The scale is administered by trained clinicians. Change = (Week 4 or Week 8 total score - Baseline total score). Negative changes indicate improvement (reduction) in depressive symptoms.

    Time frame: Baseline, Week 4, and Week 8

  6. Change From Baseline in SF-36 Physical Component Summary (PCS) Score

    The SF-36 is a validated 36-item self-reported questionnaire that assesses health-related quality of life across 8 domains (scores 0-100, higher = better). The Physical Component Summary (PCS) is a norm-based summary score derived from weighted factor analysis of the 8 domains, standardized to a general population mean of 50 and standard deviation of 10 (higher scores indicate better physical health-related quality of life). Chinese mainland adapted version (validated by Li et al., Zhejiang University, Hangzhou community norms) used. Change = (Week 4 or Week 8 PCS score - Baseline PCS score). Positive changes indicate improvement in physical health-related quality of life. Administered via self-report with guidance from study personnel.

    Time frame: Baseline, Week 4, and Week 8

  7. Change From Baseline in SF-36 Mental Component Summary (MCS) Score

    The SF-36 is a validated 36-item self-reported questionnaire that assesses health-related quality of life across 8 domains (scores 0-100, higher = better). The Mental Component Summary (MCS) is a norm-based summary score derived from weighted factor analysis of the 8 domains, standardized to a general population mean of 50 and standard deviation of 10 (higher scores indicate better mental health-related quality of life). Chinese mainland adapted version (validated by Li et al., Zhejiang University, Hangzhou community norms) used. Change = (Week 4 or Week 8 MCS score - Baseline MCS score). Positive changes indicate improvement in mental health-related quality of life. Administered via self-report with guidance from study personnel.

    Time frame: Baseline, Week 4, and Week 8

  8. Incidence of Major Adverse Cardiovascular Events (MACE) Within 8 Weeks of Treatment

    Major Adverse Cardiovascular Events (MACE) is a composite safety endpoint defined as the occurrence of any of the following events during the 8-week treatment period: Cardiovascular death Non-fatal myocardial infarction (MI) Non-fatal stroke Hospitalization for unstable angina requiring urgent revascularization Other protocol-defined major cardiovascular events (if applicable, e.g., severe heart failure exacerbation or resuscitated cardiac arrest) The incidence rate is calculated as the proportion of participants experiencing at least one MACE event (number of participants with ≥1 event / total number of participants in the analysis population × 100%). Events are adjudicated by an independent clinical events committee (if applicable) or by the investigator based on clinical records, ECG, biomarkers, and imaging. This outcome is assessed for safety monitoring and exploratory comparison between treatment arms.

    Time frame: From randomization (baseline) through Week 8 (end of treatment period)

Other outcomes

  1. Vital Signs (Body Temperature)

    Vital signs are monitored as a key safety parameter to evaluate the physiological tolerability and potential adverse effects of the investigational treatment. Body temperature (°C) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.

    Time frame: Baseline, Week 8

  2. Vital Signs (Pulse Rate)

    Vital signs are monitored as a key safety parameter to evaluate the physiological tolerability and potential adverse effects of the investigational treatment. Pulse rate (beats per minute, bpm) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.

    Time frame: Baseline, Week 8

  3. Vital Signs (Respiratory Rate)

    Vital signs are monitored as a key safety parameter to evaluate the physiological tolerability and potential adverse effects of the investigational treatment. Respiratory rate (breaths per minute) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.

    Time frame: Baseline, Week 8

  4. Vital Signs (Blood Pressure)

    Vital signs are monitored as a key safety parameter to evaluate the physiological tolerability and potential adverse effects of the investigational treatment. Blood pressure (systolic and diastolic, mmHg) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) are recorded and reported separately.

    Time frame: Baseline, Week 8

  5. Laboratory Parameters (Hematology-Red Blood Cell count)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Red Blood Cell count (RBC) Unit: ×10¹²/L (Number of red blood cells per liter of blood × 10¹²) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  6. Laboratory Parameters (Hematology-White Blood Cell count)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): White Blood Cell count (WBC) Unit: ×10⁹/L (Number of white blood cells per liter of blood × 10⁹) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  7. Laboratory Parameters (Hematology- Platelet count)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Platelet count (PLT) Unit: ×10⁹/L (Number of platelets per liter of blood × 10⁹) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  8. Laboratory Parameters (Hematology-Hemoglobin )

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Hemoglobin (Hb)-Hemoglobin Concentration Unit: g/L (grams per liter) or g/dL All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  9. Laboratory Parameters (Liver Function-Alanine Aminotransferase)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Alanine Aminotransferase (ALT) Unit: U/L (units per liter) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  10. Laboratory Parameters (Liver Function- Aspartate Aminotransferase)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Aspartate Aminotransferase (AST) Unit: U/L (units per liter) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  11. Laboratory Parameters (Liver Function-Total Bilirubin)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Total Bilirubin (TBIL) Unit: μmol/L (micromoles per liter) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  12. Laboratory Parameters (Liver Function-Alkaline Phosphatase)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function:Alkaline Phosphatase (ALP) Unit: U/L (units per liter) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  13. Laboratory Parameters (Renal Function- Serum Creatinine )

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Renal Function: Serum Creatinine (Scr) Unit: μmol/L (micromoles per liter) or mg/dL All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  14. Laboratory Parameters (Urinalysis-Protein )

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Protein (PRO) Unit: Qualitative/Semi-quantitative, typically reported as: Negative (-), Trace (±), +, ++, +++, ++++ (or mg/dL, g/L) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  15. Laboratory Parameters (Urinalysis-Glucose )

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Glucose (GLU) Unit: Qualitative/Semi-quantitative, typically reported as: Negative (-), Trace (±), +, ++, +++, ++++ (or mmol/L, mg/dL) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  16. Laboratory Parameters (Urinalysis-Erythrocytes)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Erythrocytes (ERY) Unit: per high-power field (/HPF) or per microliter (μL) (microscope count) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  17. Laboratory Parameters (Urinalysis-Leukocytes)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Leukocytes (LEU) Unit: per high-power field (/HPF) or per microliter (μL) (microscope count) All tests are conducted using standardized clinical laboratory methods at a certified central or local laboratory. Clinically significant abnormalities or changes are evaluated and reported as adverse events per protocol criteria.

    Time frame: Baseline, Week 8

  18. Heart Rate on 12-lead electrocardiogram

    Heart rate (beats per minute) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Used for cardiac safety monitoring. Clinically significant changes are reported as adverse events. Unit of Measure: beats per minute (bpm)

    Time frame: Baseline, Week 4, Week 8

  19. PR Interval on 12-lead electrocardiogram

    PR interval (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Assessed as part of cardiac conduction safety evaluation. Clinically significant prolongation is reported as an adverse event. Unit of Measure: milliseconds (ms)

    Time frame: Baseline, Week 4, Week 8

  20. QRS Duration on 12-lead electrocardiogram

    QRS duration (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Monitored for potential ventricular conduction abnormalities. Clinically significant changes are reported as adverse events. Unit of Measure: milliseconds (ms)

    Time frame: Baseline, Week 4, Week 8

  21. QT Interval on 12-lead electrocardiogram

    QT interval (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Used for cardiac repolarization safety assessment. Unit of Measure: milliseconds (ms)

    Time frame: Baseline, Week 4, Week 8

  22. Corrected QT Interval (QTc) on 12-lead electrocardiogram

    Corrected QT interval (QTc, milliseconds) is calculated from the QT interval on a standard 12-lead electrocardiogram (recorded after ≥5 minutes rest, supine position, calibrated equipment) using Bazett or Fridericia formula as specified in the protocol. Interpreted by qualified cardiologists or trained investigators. QTc prolongation (e.g., \>500 ms) is considered clinically significant and reported as an adverse event. Key cardiac safety parameter. Unit of Measure: milliseconds (ms)

    Time frame: Baseline, Week 4, Week 8

  23. "Shang Huo" (Excess Heat) Symptoms Score

    "Shang Huo" often translated as excess internal heat or fire syndrome in Traditional Chinese Medicine. Key symptoms include: Dry mouth / thirst; Oral ulcers or sores on tongue/mouth; Swollen and painful gums; Increased appetite with easy hunger; Constipation; Other possible accompanying symptoms (e.g., sore throat, red eyes, irritability, if protocol-defined).

    Time frame: Baseline, Week 4, Week 8, Week 12

  24. Incidence, Severity, Timing, and Relationship of Adverse Events (AEs)

    Adverse events will be evaluated in terms of type, incidence, severity, time of onset, and relationship to the study drug. Types of adverse events are classified as: Adverse Event (AE), Serious Adverse Event (SAE), and Suspected Unexpected Serious Adverse Reaction (SUSAR). Severity is graded as: mild, moderate, or severe. Mild: The subject can tolerate the event; it does not interfere with ongoing treatment, requires no special intervention, and has no impact on the subject's recovery. Moderate: The subject finds the event difficult to tolerate; it necessitates discontinuation of the study drug or special treatment, and it directly affects the subject's recovery. Severe: The event is life-threatening, results in death or permanent disability/incapacity, and requires immediate discontinuation of the study drug or emergency intervention.

    Time frame: Week 4, Week 8, Week 12/EOS/EOT

  25. Pharmacokinetic (PK) Parameters-Plasma Maximum Observed Concentration (Cmax)

    Plasma concentration measured from blood samples collected opportunistically at Week 4 (or Week 8/early discontinuation). Cmax is the maximum observed concentration post-dose. Parameters estimated using non-compartmental analysis or population PK modeling due to sparse sampling. Geometric mean and variability reported. Assessed as an exploratory pharmacokinetic biomarker. Unit of Measure: ng/mL (or appropriate unit, e.g., nmol/L)

    Time frame: Baseline, Week 4, Week 8

  26. Pharmacokinetic (PK) Parameters-Plasma Trough Concentration (Ctrough)

    Blood samples collected opportunistically at Week 4 and at Week 8 (or early termination), ideally at pre-dose timing where possible. Plasma concentration of \[Drug Name\] measured using validated bioanalytical methods. Ctrough is the observed minimum concentration at the end of the dosing interval. Reported as geometric mean and variability. Exploratory pharmacokinetic endpoint focusing on steady-state trough exposure. Unit of Measure: ng/mL (or nmol/L, adjust based on drug)

    Time frame: Baseline, Week 4, Week 8

  27. Pharmacokinetic (PK) Parameters-Time Curve (AUC0-last)

    Area under the concentration-time curve from time zero to the last measurable concentration (AUC0-last) , estimated from sparse opportunistic sampling at Week 4 (or Week 8) using population PK methods. Geometric mean reported. Exploratory PK biomarker of exposure. Unit of Measure: h·ng/mL (or appropriate, e.g., h·nmol/L

    Time frame: Baseline, Week 4, Week 8

  28. Fecal Multi-Omics Profile

    Fecal samples collected at baseline and Week 8 . Multi-omics analysis (including gut microbiome profiling via 16S rRNA sequencing or metagenomics, and fecal metabolomics via targeted/untargeted methods) performed to assess overall changes in microbial composition, diversity, and metabolic products (e.g., short-chain fatty acids and other microbial-derived metabolites). Changes from baseline evaluated as exploratory biomarkers of treatment effects on gut microbiota and related metabolic pathways. Unit of Measure: Varies by assay (e.g., relative abundance %, μmol/g feces, diversity indices)

    Time frame: Baseline, Week 8

  29. Plasma Multi-Omics Profile

    Blood samples collected at baseline, Week 4 (opportunistic sampling), and Week 8. Multi-omics analysis (including targeted/untargeted metabolomics and proteomics) performed on plasma to assess systemic changes in metabolites (e.g., tryptophan pathway intermediates) and proteins (e.g., inflammatory markers or neurotrophic factors). Changes from baseline evaluated as exploratory biomarkers of treatment effects on systemic metabolism and inflammation. Unit of Measure: Varies by assay (e.g., nmol/L or pg/mL)

    Time frame: Baseline, Week 4, Week 8

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

Of 16 phase 2 interventional studies under Myocardial Ischemia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2026
First posted
Mar 17, 2026
StartEst.
Mar 8, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07478328
Lead sponsor
Longhua Hospital
Collaborators
Shanghai University of Traditional Chinese Medicine, DongE E Jiao Coporation Limited
Responsible party
Suyun Yuan (Chief Physician, Longhua Hospital) — Principal investigator
First posted
Mar 17, 2026
Start date
Mar 8, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 17, 2026

Study contacts

Jia hong Jin, Ph.D
Contact
370708790@qq.com
17321231717 ext. 021-64385700
Su yun Yuan, Ph.D
principal investigator · Shanghai University of Traditional Chinese Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion